Abstract: In a push back cart rack storage system, the top or first cart, as well as the second cart, may be made with less material, and may be significantly simpler and lighter in comparison to existing designs. A push-back cart storage system has a single pair of push-back rails in each lane. A third cart has front and back wheels rolling on a lower inside flange of the push-back rails. A second cart has front wheels rolling on a lower inside cart flange of side rails of the third cart, and has rear wheels rolling on the lower inside flange of the push-back rails. A first or top cart has front and rear wheels rolling on a top surface of the push-back rails. The wheels on the first cart may be inner facing wheels while the wheels on the other carts may be outer facing wheels. The push-back rails and the side rails of the carts may be generally C-shaped channel sections.

Abstract: The present invention relates to the chemical products of general formula: ##STR1## in which R.sub.1 and R.sub.2 designate hydrogen; halogen, lower alkyl or lower alkoxy; R.sub.3 and R.sub.4 designate hydrogen, alkyl, alkoxy, halogen, nitro, acyl, alkylthio, alkylsulfinyl, alkylsulfonyl, a (CH.sub.2).sub.n COOR, (CH.sub.2).sub.2 CONHR, (CH.sub.2).sub.n NHCOOR or (CH.sub.2).sub.n NHCOR group; or R.sub.3 and R.sub.4 together form a heterocycle bonded to the benzene cycle; X.sub.1 is hydrogen, alkyl, hydroxymethyl or COOR and X.sub.2 is hydrogen or methyl; and to the pharmaceutically acceptable salts of said products. It also relates to a process for preparing said products and to the drugs active in particular on the cardiovascular system, containing at least one of said products.

Abstract: Carcinostatic products are formed by coupling, by covalent bonding, the A chain of ricin with an antibody which is capable of selectively recognizing a given antigen at the surface of cancerous cells. Such products can be made by the formation of a disulphide bridge between the free thiol group in the A chain of ricin and an immunoglobulin or immunoglobulin fragment into which a thiol group or an activated disulphide group has been introduced. The A chain of ricin and the immunoglobulin are carefully purified before use.

Abstract: The present invention relates to a new process for the stepwise preparation of somatostatin enabling a product of high purity to be obtained, with high yields, from cysteine in 14 position whose acid function is protected by the phenylazobenzylsulfonylethyloxy group and thiol function is protected by the acetamidomethyl group, all the peptide coupling reactions being effected in liquid phase in the dimethylformamide, the intermediate peptides being precipitated by addition of a second solvent and purified in solid phase by washing with the aid of suitable solvents dissolving the impurities.

Abstract: The present invention relates to phenoxypropane having the formula ##STR1## in which R.sup.1 and R.sup.2 are like or unlike and each is an alkyl group having 1-4 carbon atoms, R.sup.3 is hydrogen or an alkyl group having 1-4 carbon atoms, R.sup.4 is a halogen atom, preferably fluorine, chlorine or bromine, including their optical isomers and also their addition salts with acids.These compounds are of therapeutic value in the treatment of cardiovascular conditions.The invention also relates to methods of synthesis of these products including a synthesis which involves the production, as a intermediate of an 8-aza-4,9-dioxa-2,3-benzo-bicyclo-[4,2,1]-octane having the formula ##STR2## in which R.sup.1 and R.sup.4 are as above defined.

Abstract: Talampicillin 2-methoxyphenoxyacetate; a process for its preparation by acid hydrolysis of the metampicillin phthalidyl ester in a biphasic aqueous-organic solvent and treatment of the resulting aqueous phase with an alkali metal salt of the 2-methoxyphenoxyacetic acid; and pharmaceutical compositions containing said talampicillin 2-methoxyphenoxyacetate as an active ingredient.

Abstract: Compositions having therapeutic value in the treatment of cardiovascular conditions associated with the overproduction of catecholamines include as the active ingredient 5-fluoro-2-(2-hydroxy-3-tertiary butyl-amino-propoxy) butyrophenone-, its optical isomers and non-toxic acid addition salts.

Abstract: The invention relates to benzodiazepine compounds of the formula: ##STR1## wherein R.sub.5 is C.sub.1 -C.sub.4 alkyl, R.sub.3 is C.sub.1 -C.sub.4 alkyl, and R.sub.4 is selected from Cl and F, and medicaments containing such benzodizepine compounds.

Abstract: The present invention relates to a treatment of the "hyperkinetic syndrome" in children, wherein a medicine containing between 50 and 200 mg of 3-morpholino-ethylamino 4-methyl 6-phenylpyridazine is administered daily to patients, by oral route.

Abstract: Novel derivatives of midecamycine, of the formula: ##STR1## wherein X represents an oxygen atom or a sulphur atom, R.sub.1 represents a straight or branched alkyl group, an alkenyl group or an aryl group, R.sub.2 represents a hydrogen atom or a lower acyl group, the dotted lines represent the possible presence of double bonds, it being understood that the 2 double bonds at the 10,11 position on the one hand and the 12,13 position on the other either exist simultaneously or neither of them exists, which give by oral administration plasma rates which are higher than midecamycine and which lack its bitter taste, together with their process of preparation.

Abstract: Compounds having psychostimulant, antispasmodic, hypotensive and analgesic properties are disclosed. The compounds have the formula: ##STR1## in which R.sup.2 is selected from the group consisting of a hydrogen atom and a halogen atom;R.sup.1 is selected from the group consisting of a cyclohexyl group and a phenyl group, and is a cyclohexyl group when R.sup.2 is a halogen atom;A is selected from the group consisting of CH.sub.2 CH.sub.2 and CH.dbd.CH groups; andNr.sup.3 r.sup.4 is selected from the group consisting of an alkylamino group, a dialkylamino group and a heterocyclic ring containing from 5 to 7 atoms in the ring, said ring optionally having one or more sbustituents and optionally containing a second hetero-atom; and acid addition salts of said compounds.

Abstract: A process for the manufacture of benzodiazepine derivatives which comprises reacting 2-amino-5-chloro-benzophenone with a primary amine H.sub.2 N--R.sub.1 to give an imine which is reacted with an amino-ester ##STR1## to give a ketimine said ketimine being then converted to a benzodiazepine derivative.